Sep. 5 at 3:48 AM
$APVO Phase 1 Clinical Trial Stage (
$500M –
$3B): Entering human trials and proving basic safety profiles dramatically escalates a platform's worth. Even with early data, large pharmaceutical companies are willing to pay massive premiums to secure differentiated technology. A prime example is Poseida Therapeutics, which was acquired by Roche for up to
$1.5 billion to capture their next-generation, off-the-shelf CAR-T platform.
Explain how we’re trading at
$3.5 million valuation? 2 million shares, 8 million shares, 20 million shares. I don’t care. No matter what the count is, we’re so far undervalued it’s silly. Take the most conservative average valuation and divide by the full OS share count with full warrant exercise and you get
$62.50/share. And we’re at
$1.74. Huh?
